CELLULAR SIGNALLING, published by Elsevier Science Inc, is a premier journal within the realm of Cell Biology, boasting an impressive Q2 category ranking as of 2023. With an ISSN of 0898-6568 and an E-ISSN of 1873-3913, the journal has established itself as a critical platform for advancing the understanding of cellular mechanisms and signal transduction pathways since its inception in 1989. Covering a vast array of topics in Biochemistry, Genetics, and Molecular Biology, it ranks notably at 87 out of 285 in the Scopus list, placing it in the 69th percentile among its peers. The journal serves as an invaluable resource for researchers, professionals, and students seeking high-quality, impactful studies that drive forward the field of cellular biology. While it operates under traditional subscription access, its highlights include rigorous peer-reviewed articles, reviews, and insights that continue to shape current scientific discourse.

The Journal of Cell Communication and Signaling is a prestigious academic journal published by Springer, focused on advancing the understanding of cellular communication mechanisms and signaling pathways. Since its inception in 2007, this journal has established itself as a leading platform in the field, with a strong impact reflected in its 2023 categorizations: Q1 in Biochemistry, Q2 in Cell Biology, and Q2 in Molecular Biology. Researchers from around the globe rely on its rigorous peer-reviewed articles to gain insights into the complex molecular dialogue that underpins various biological processes. With an ISSN of 1873-9601 and E-ISSN of 1873-961X, the journal is committed to disseminating high-quality research that informs both academic studies and practical applications in biotechnology and medicine. Although not an open access publication, it provides essential resources tailored for professionals, students, and researchers, enhancing their knowledge of critical signaling pathways that drive health and disease. The journal is located in the Netherlands, at VAN GODEWIJCKSTRAAT 30, DORDRECHT, and stands out in the field, boasting impressive ranks among its peers in the Scopus database.

International Journal of Molecular Medicine is a prestigious publication dedicated to advancing the field of molecular medicine through innovative research and scholarly dialogue. Published by Spandidos Publications Ltd in Greece, this journal has successfully provided a platform for academics and professionals alike since its inception in 1998. With an impressive 2023 Q1 ranking in Medicine (Miscellaneous) and a Q2 ranking in Genetics, the journal maintains a vital role in disseminating high-quality research, underscored by its strong performance in the Scopus rankings, particularly in the realm of genetics where it ranks 28 out of 347. Researchers will benefit from its comprehensive scope, which encompasses a wide range of topics within molecular biology, genetics, and their clinical applications. Although the journal does not operate under an open access model, it remains influential, providing critical insights that contribute significantly to the understanding and development of molecular therapeutic strategies and innovations.

Cancer Communications, published by WILEY, is a leading open-access journal that has positioned itself at the forefront of cancer research and oncology since its inception in 2017. With an impressive HIndex reflective of its scholarly impact and recognized in the Q1 category for both Cancer Research and Oncology as of 2023, this journal consistently ranks in the top echelons of its field, specifically at Rank #16/404 and Rank #13/230 in their respective categories on Scopus. Cancer Communications aims to disseminate cutting-edge research findings, innovative methodologies, and significant advancements in cancer treatments, thereby fostering a deeper understanding of oncology among researchers, healthcare professionals, and students. The journal operates under an Open Access model since 2018, ensuring that vital research is accessible to a global audience, thus enhancing collaboration and knowledge sharing necessary to tackle one of the most pressing health challenges of our time. Located in Hoboken, NJ, United States, and with a strong commitment to scientific excellence, Cancer Communications remains an essential resource for anyone engaged in the fight against cancer.

INTERNATIONAL JOURNAL OF ONCOLOGY is a leading academic publication dedicated to advancing the field of cancer research and treatment. Published by SPANDIDOS PUBL LTD in Greece, this journal, with ISSN 1019-6439 and E-ISSN 1791-2423, has established itself as a reputable source of peer-reviewed articles since its inception in 1993. With an impressive Q2 ranking in both Cancer Research and Oncology categories, as well as high Scopus ranks reflecting its significant contribution to the fields of Medicine and Biochemistry, the journal offers a platform for researchers, clinicians, and students alike to disseminate their findings and engage in dialogue surrounding innovative practices and breakthroughs. Although the journal follows a traditional subscription model, it continues to attract a diverse readership interested in the latest developments in oncological research, providing essential insights into cancer biology, therapeutics, and patient care. With a commitment to excellence, the INTERNATIONAL JOURNAL OF ONCOLOGY plays a vital role in shaping the future of oncology research and is a must-read for anyone passionate about advancing cancer treatment and prevention.

The Journal of Gene Medicine, published by Wiley, stands as a pivotal resource in the field of gene therapy and molecular medicine, with a rich history of dissemination of impactful research since its inception in 1998. With an ISSN of 1099-498X and an E-ISSN of 1521-2254, this esteemed journal plays a crucial role in advancing our understanding of genetics and drug discovery, reflected in its impressive 2023 Scopus rankings where it holds a Q2 classification in Drug Discovery and Q3 in several genetics-related categories. The journal aims to facilitate the exchange of high-quality research findings that bridge the gap between laboratory and clinical applications, making it an essential platform for researchers, academics, and healthcare professionals committed to the forefront of genetic innovation. Although it does not currently offer open access options, its reputation for rigorous peer review ensures that all published work meets the highest academic standards, providing a reliable reference for scientific inquiry in the United States and beyond. As the field rapidly evolves, the Journal of Gene Medicine remains at the helm, guiding future discoveries with its influential publications and comprehensive insights.

Non-coding RNA Research, published by KEAI PUBLISHING LTD, is a leading open-access journal dedicated to advancing the field of non-coding RNA, a critical component in the landscape of molecular biology and genetics. Established in 2016, this journal aims to provide a platform for the dissemination of high-quality research focusing on the roles, mechanisms, and therapeutic potentials of non-coding RNAs in various biological processes and diseases. With impressive Scopus rankings placing it in the top quartile for both Biochemistry and Medical Biochemistry, as well as notable standings in Genetics and Molecular Biology, Non-coding RNA Research continues to attract contributions from globally recognized experts. The journal's commitment to open access ensures broad visibility and engagement with cutting-edge discoveries, thereby fostering an inclusive scientific dialogue that enhances understanding and innovation in this rapidly evolving field. For researchers and scholars, the opportunity to publish in a Q1 ranked journal not only validates their work but also enhances its impact, making Non-coding RNA Research an indispensable resource for anyone interested in the intricate workings of non-coding RNA.

Molecular & Cellular Oncology, published by Taylor & Francis Inc, is a vital academic journal dedicated to the exploration of cancer biology through the lens of molecular and cellular mechanisms. Since its inception in 2014, the journal has played a crucial role in disseminating innovative research findings that address the fundamental aspects of cancer research and molecular medicine. With its current ranking in Scopus placing it in the Q3 quartile for both Cancer Research and Molecular Medicine, the journal provides a platform for groundbreaking studies that push the boundaries of our understanding of oncogenesis and therapeutic interventions. Although the journal operates under a subscription model, its dedication to high-quality peer-reviewed research makes it an essential resource for researchers, professionals, and students aiming to contribute to or stay updated in the rapidly evolving field of oncology. As we approach the culmination of its converged years in 2024, Molecular & Cellular Oncology aims to continue fostering collaborations and insights that advance cancer research on a global scale.

Cell Death Discovery, published by Springer Nature, is a distinguished open-access journal dedicated to advancing the field of cell death research. Since its inception in 2015, the journal has rapidly established itself as a premier platform for high-quality research, currently holding a remarkable position in the Q1 quartiles across multiple categories, including Cancer Research, Cell Biology, Cellular and Molecular Neuroscience, and Immunology. With an impact factor reflecting its significant contribution to the scientific community, Cell Death Discovery invites submissions that explore the molecular mechanisms of cell death and its implications across various biomedical fields. The journal's open-access model ensures that groundbreaking research is accessible to a global audience, facilitating collaboration and dissemination among researchers, professionals, and students alike. Located in the UK, at CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND, the journal continues to support innovative scholarship and foster a deeper understanding of the processes behind cell viability, development, and disease.

CELL CYCLE, an esteemed journal published by Taylor & Francis Inc., stands at the forefront of biological research, focusing on the intricate mechanisms of cell proliferation, molecular biology, and developmental biology. With an ISSN of 1538-4101 and an E-ISSN of 1551-4005, this journal has established its influence in the field with a commendable impact factor reflecting its rigorous peer-review process and high-quality publications. Notably, in 2023, it achieved a Q1 ranking in Medicine (miscellaneous) and a Q2 ranking in both Cell Biology and Developmental Biology, marking its vital role in advancing scientific understanding and innovation. Operating within a converged framework from 2002 to 2024, CELL CYCLE caters to a diverse audience of researchers, professionals, and students eager to explore contemporary findings and emerging trends. The journal's objective is to disseminate groundbreaking research that enhances our understanding of cellular mechanisms, fostering collaboration and innovation. Although not an open-access journal, it remains a premier source for those engaged in cell cycle research, and its contributions have significant implications for fields such as healthcare, biotechnology, and genetics.